| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 933.24% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1966.47% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 1277.65% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
NLS Pharmaceutics Questions & Answers
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on November 8, 2022. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.58, which is out of the analyst's predicted range.